<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053440</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-302</org_study_id>
    <nct_id>NCT03053440</nct_id>
  </id_info>
  <brief_title>A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 vs ibrutinib
      in subjects with MYD88 Mutation Waldenström's Macroglobulinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, randomized study will compare the efficacy and safety of the Bruton's
      Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in subjects with Waldenström's
      Macroglobulinemia who require therapy. Subjects will have baseline bone marrow samples
      assayed for sequencing of the MYD88 gene. Approximately 150 subjects with the MYD88 mutation
      will be enrolled onto Cohort 1 and randomized to receive 160 mg BGB-3111 PO BID (treatment
      Arm A) or to receive 420mg ibrutinib QD (treatment Arm B) until disease progression or
      unacceptable toxicity. Subjects with MYD88 wild type will be enrolled to Cohort 2 and will
      receive 160 mg BGB-3111 PO BID (treatment Arm C) until disease progression or unacceptable
      toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving either a complete response (CR) or very good partial response (VGPR) in Cohort 1 using an adaptation of the response criteria updated at the Sixth IWWM as assessed by an independent review committee.</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measured by major response rate (MRR) in Cohort 1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>MRR defined as the proportion of subjects achieving a best response of response of CR, VGPR, or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measured by duration of response (DOR) in Cohort 1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measured by progression-free survival (PFS) in Cohort 1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>PFS defined as time from randomization to the first documentation of progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of treatment-precipitating symptoms in Cohort 1, measured by the absence of the symptoms that triggered initiation of study treatment (per the IWWM treatment guidelines) at any point during study treatment</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-lymphoma effect in Cohort 1, as measured by any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or hepatosplenomegaly</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by the incidence, timing, and severity of treatment-emergent AEs in Cohort 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of AEs of Special Interest in Cohort 1</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Waldenström's Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm A (Experimental Arm-BGB-3111)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 75 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Active Comparator-Ibrutinib)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately 75 subjects with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Experimental Arm-BGB-3111)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 15-20 subjects found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>160mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor</description>
    <arm_group_label>Arm A (Experimental Arm-BGB-3111)</arm_group_label>
    <arm_group_label>Arm C (Experimental Arm-BGB-3111)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>420mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor</description>
    <arm_group_label>Arm B (Active Comparator-Ibrutinib)</arm_group_label>
    <other_name>IMBRUVICA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and definitive histologic diagnosis of WM

          -  Measurable disease, requiring treatment

          -  Patients with no prior therapy for WM, must be considered inappropriate candidates
             for treatment with a standard chemoimmunotherapy regimen

          -  Age ≥ 18 years old

          -  (ECOG) performance status of 0-2

          -  Adequate bone marrow function

          -  Adequate renal and hepatic function

          -  ECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)≥ the lower limit of
             institutional normal

          -  Subjects may be enrolled who relapse after autologous stem cell transplant if they
             are at least 3 months after transplant, and after allogeneic transplant if they are
             at least 6 months post transplant.

          -  Females of childbearing potential must agree to use highly effective forms of birth
             control throughout the course of the study and at least up to 90 days after last dose
             of study drug. Males must have undergone sterilization- vasectomy, or utilize a
             barrier method

          -  Life expectancy of &gt; 4 months

        Exclusion Criteria:

          -  Prior exposure to a BTK inhibitor

          -  Evidence of disease transformation at the time of study entry

          -  Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy given
             with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or
             antibody-based therapy within 4 weeks of the start of study drug

          -  Major surgery within 4 weeks of study treatment

          -  Toxicity of ≥ Grade 2 from prior anticancer therapy

          -  History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             with curative intent

          -  Currently active, clinically significant cardiovascular disease such as uncontrolled
             arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6
             months of screening

          -  QTcF prolongation (defined as a QTcF &gt; 450 msec)

          -  Active, clinically significant Electrocardiogram (ECG) abnormalities

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction

          -  Uncontrolled active systemic infection or recent infection requiring parenteral
             anti-microbial therapy

          -  Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C

          -  Pregnant or lactating women

          -  Any life-threatening illness, medical condition, organ system dysfunction, need for
             profound anticoagulation, or bleeding disorder, which, in the investigator's opinion,
             could compromise the subject's safety

          -  Any medications which are strong or moderate cytochrome P450, family 3, subfamily A
             (CYP3A) inhibitors or strong CYP3A inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jane Huang, MD</last_name>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medial College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Furman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Furman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantine Tam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Constantine Tam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge - Oostende - Campus Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Van Droogenbroeck</last_name>
    </contact>
    <investigator>
      <last_name>Jan Van Droogenbroeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Hämatologie und Onkologie</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Lenz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Georg Lenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Alexandra&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meletios Dimopoulus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meletios Dimopoulus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PU A. Gemelli, Universität Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Laurenti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luca Laurenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Jose Kersten, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie Jose Kersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Małopolskie Centrum Medyczne</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wojciech Jurczak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wojciech Jurczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U. Vall d´Herbon</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Gironella Mesa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Gironella Mesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Center Karolinska</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wahlin Björn, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wahlin Björn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shirley P D'sa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shirley P D'sa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 12, 2017</lastchanged_date>
  <firstreceived_date>February 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
